Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

NCT00416793 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to poor accrual

Conditions

Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer

Interventions

DRUG: bortezomib
DRUG: carboplatin
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)